Brind.
  1. Quoin Pharmaceuticals Ltd., which focuses on rare and orphan diseases, is developing investigational candidate QRX003 for Netherton Syndrome. Denise Carter serves as Co-Founder and COO.

Quoin Pharmaceuticals received Rare Pediatric Disease and Orphan Drug status from FDA and EMA for its Netherton Syndrome candidate.

1 report, 0 independent Updated Jun 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Quoin Pharmaceuticals received Rare Pediatric Disease and Orphan Drug status from FDA and EMA for its Netherton Syndrome candidate.

Who's involved

What this event is mainly about
FDA

Keep exploring

Part of

Quoin Pharmaceuticals Ltd., which focuses on rare and orphan diseases, is developing investigational candidate QRX003 for Netherton Syndrome. Denise Carter serves as Co-Founder and COO. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet